A Phase I study of STI-A1015 (IMC-001) in patients suffering from solid tumors
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs STI-A1015 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Feb 2018 New trial record
- 05 Feb 2018 According to a Sorrento Therapeutics media release, the company is planning to conduct Phase 1 studies at two clinical sites in South Korea, namely, Seoul National University Hospital (SNUH) and Samsung Medical Center (SMC).
- 05 Feb 2018 According to a Sorrento Therapeutics media release, the South Korean Ministry of Food and Drug Safety (MFDS) has approved ImmuneOncia Therapeutics IND to initiate this trial.